Schultes 1998.

Methods	Retrospective uncontrolled study
Participants	75 stage I‐IV ovarian cancer patients (disease status at study entry not described)
Interventions	Intravenous monoclonal antibody (oregovomab ‐ CA‐125)
Outcomes	Survival (overall survival) Immune responses: humoral (Ab2, Ab3, HAMA)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’